Protagonist Therapeutics, Inc Cash and Cash Equivalents
Protagonist Therapeutics, Inc (PTGX) had Cash and Cash Equivalents of $420.08 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $420.08M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $193.71M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $128.39M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $113.71M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $420.08M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $193.71M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $128.39M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $113.71M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $168.54M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $139.65M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $97.25M 10-K · filed 2026-02-25 |
| 2024-09-30 | $131.12M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $355.64M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $172.57M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $186.73M 10-K · filed 2026-02-25 |
| 2023-09-30 | $230.53M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $235.38M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $127.69M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $125.74M 10-K · filed 2025-02-21 |
| 2022-09-30 | $152.82M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $120.24M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $98.48M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $123.67M 10-K · filed 2024-02-27 |
| 2021-09-30 | $120.54M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $192.41M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $83.00M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $117.36M 10-K · filed 2023-03-15 |
| 2020-09-30 | $83.63M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $146.24M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $60.22M 10-Q · filed 2021-05-04 |
| 2019-12-31 | $33.01M 10-K · filed 2022-02-28 |
| 2019-09-30 | $50.20M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $71.14M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $70.08M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $82.23M 10-K · filed 2021-03-10 |
| 2018-09-30 | $87.43M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $63.86M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $69.58M 10-Q · filed 2019-05-08 |
| 2017-12-31 | $106.03M 10-K · filed 2020-03-10 |
| 2017-09-30 | $50.40M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $10.37M 10-Q · filed 2018-08-07 |
| 2017-03-31 | $9.52M 10-Q · filed 2018-05-09 |
| 2016-12-31 | $21.08M 10-K · filed 2019-03-12 |
| 2016-09-30 | $96.02M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $13.77M 10-Q · filed 2017-08-08 |
| 2016-03-31 | $28.63M 10-Q · filed 2017-05-10 |
| 2015-12-31 | $4.05M 10-K · filed 2018-03-07 |
| 2015-09-30 | $16.71M 10-Q · filed 2016-11-14 |
| 2015-06-30 | $3.40M 10-Q · filed 2016-09-15 |
| 2014-12-31 | $9.32M 10-K · filed 2017-03-07 |
| 2013-12-31 | $8.46M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |